Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in pediatric relapsed/refractory solid tumors
NCT04447755Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 2 trial of lenvatinib in Ewing sarcoma, rhabdomyosarcoma (RMS), glioma, diffuse midline glioma (DMG), medulloblastoma, sponsored by Merck & Co.. Started Jul 2020; status: completed.
02
Drugs
lenvatinib
03
Conditions
Ewing sarcomarhabdomyosarcoma (RMS)gliomadiffuse midline glioma (DMG)medulloblastoma
Beyond the preview
Go deeper on NCT04447755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447755.